<PubmedArticle>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">15551199</PMID>
<DateCompleted>
<Year>2005</Year>
<Month>02</Month>
<Day>14</Day>
</DateCompleted>
<DateRevised>
<Year>2018</Year>
<Month>12</Month>
<Day>01</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0176-3679</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>37</Volume>
<Issue>6</Issue>
<PubDate>
<Year>2004</Year>
<Month>Nov</Month>
</PubDate>
</JournalIssue>
<Title>Pharmacopsychiatry</Title>
<ISOAbbreviation>Pharmacopsychiatry</ISOAbbreviation>
</Journal>
<ArticleTitle>EEG abnormalities under treatment with atypical antipsychotics: effects of olanzapine and amisulpride as compared to haloperidol.</ArticleTitle>
<Pagination>
<MedlinePgn>304-5</MedlinePgn>
</Pagination>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Pogarell</LastName>
<ForeName>O</ForeName>
<Initials>O</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Juckel</LastName>
<ForeName>G</ForeName>
<Initials>G</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Mulert</LastName>
<ForeName>C</ForeName>
<Initials>C</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Amann</LastName>
<ForeName>B</ForeName>
<Initials>B</Initials>
</Author>
<Author ValidYN="Y">
<LastName>MÃ¶ller</LastName>
<ForeName>H-J</ForeName>
<Initials>HJ</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Hegerl</LastName>
<ForeName>U</ForeName>
<Initials>U</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D003160">Comparative Study</PublicationType>
<PublicationType UI="D016422">Letter</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>Germany</Country>
<MedlineTA>Pharmacopsychiatry</MedlineTA>
<NlmUniqueID>8402938</NlmUniqueID>
<ISSNLinking>0176-3679</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>12794-10-4</RegistryNumber>
<NameOfSubstance UI="D001569">Benzodiazepines</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>7MNE9M8287</RegistryNumber>
<NameOfSubstance UI="D013469">Sulpiride</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>8110R61I4U</RegistryNumber>
<NameOfSubstance UI="D000077582">Amisulpride</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>J6292F8L3D</RegistryNumber>
<NameOfSubstance UI="D006220">Haloperidol</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>N7U69T4SZR</RegistryNumber>
<NameOfSubstance UI="D000077152">Olanzapine</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000077582">Amisulpride</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D014150">Antipsychotic Agents</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001569">Benzodiazepines</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016009">Chi-Square Distribution</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004305">Dose-Response Relationship, Drug</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004569">Electroencephalography</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005500">Follow-Up Studies</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006220">Haloperidol</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000077152">Olanzapine</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012559">Schizophrenia</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000503">physiopathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D013469">Sulpiride</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000031">analogs &amp; derivatives</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
<PubMedPubDate PubStatus="pubmed">
<Year>2004</Year>
<Month>11</Month>
<Day>20</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline">
<Year>2005</Year>
<Month>2</Month>
<Day>16</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez">
<Year>2004</Year>
<Month>11</Month>
<Day>20</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
<ArticleId IdType="pubmed">15551199</ArticleId>
<ArticleId IdType="doi">10.1055/s-2004-832690</ArticleId>
</ArticleIdList>
</PubmedData>
</PubmedArticle>